FDA approves first twice-yearly injection that prevents HIV infection
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.
Sold under the name Yeztugo, the company's injectable HIV-1 capsid inhibitor (lenacapavir) reduces the risk of sexually acquired HIV in adults and adolescents.
"This is a historic day in the decades-long fight against HIV," said Daniel O'Day, chairman and CEO of California-based Gilead Sciences, in a press release.
The medicine, which only needs to be administered twice a year, has shown "remarkable outcomes in clinical studies," as Gilead claims it could transform HIV prevention.
The drug is given as an injectable under the skin that the body then slowly absorbs. Individuals must have a negative HIV-1 test prior to starting the treatment.
In large trials last year, the drug was not only nearly 100% effective in its prevention of HIV, but proved superior to once-daily oral medication like Truvada, another drug by Gilead.
The journal Science named lenacapavir its 2024 "Breakthrough of the Year."
Lenacapavir uses a multi-stage approach that distinguishes it from other approved antiviral medications.
"While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle," states the press release from Gilead.
For more Health articles, visit www.foxnews.com/health
"Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," O'Day said in the press release.
The most commonly reported adverse reactions during clinical trials included injection site reactions, headache and nausea, according to the company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
18 minutes ago
- CNN
Plastic shopping bag policies are actually working, a new study suggests
Sign up for CNN's Life, But Greener newsletter. Our limited newsletter series guides you on how to minimize your personal role in the climate crisis — and reduce your eco-anxiety. That extra fee at the grocery store for a plastic shopping bag isn't just an inconvenience –– it is actually making a difference for marine ecosystems, according to a new study. Policies that ban or impose fees on plastic bags are associated with a 25% to 47% decrease in plastic bag litter in shoreline cleanups, according to a study published Thursday in the journal Science. Plastic litter is a big risk to the health of marine ecosystems, and the problem is growing, said lead study author Dr. Anna Papp, an environmental economist and incoming postdoctoral researcher at the Massachusetts Institute of Technology. The United States has no federal-level policy on plastic bags, so researchers analyzed 180 local programs, including full bans, fees on shopping bags and partial bans –– which sometimes have special regulations such as requiring thicker plastics to make shopping bags reusable. Researchers then analyzed data from more than 45,000 US shoreline cleanups to compare the litter before and after the policy was passed as well as the differences between areas with and without a policy, Papp said. 'The main finding is that these policies led to a decrease in plastic bags as a share of total items collected,' she said. Other studies have shown that plastic bag policies affect how many bags consumers use, said Dr. Erin Murphy, manager of Ocean Plastics Research for the Ocean Conservancy. But this most recent research 'really takes it to the next level, showing it's not only reducing the amount of bags we're using, but it's actually achieving our broader objectives of environmental cleanliness,' she said. Plastic bag pollution is harmful to both animals and humans. On beaches or other outdoor spaces, plastic pollution can have a negative impact on tourism or the value of spending time in nature, Papp said. Plastic bag litter is particularly dangerous to marine animals for two reasons, Murphy said. First, they enter the environment more easily than other types of plastic. 'They're hard to recycle, they're single-use, and they're lightweight, and so they blow very easily in the wind. Even if we're trying to properly manage them, it's easy for them to escape waste management systems and get into the environment,' she said. Second, once they enter the environment, plastic bags can lead to population-level effects on marine species, Murphy said. Many species, including marine mammals and sea turtles, will eat the plastic bags, obstructing the gastrointestinal tract and preventing them from eating until they die, she said. Plastic bags can also entangle wildlife, keeping hatchling sea turtles from reaching the ocean and shading coral reefs, all of which can lead to disease and death for marine species. 'In 2024 alone, our International Coastal Cleanup volunteers cleaned up over 500,000 grocery bags from the environment and 500,000 other plastic bags, totaling more than a million different plastic bag types from the environment,' Murphy said. 'They're always in our top 10 items found in the environment, and that alone is an issue.' While bans and fees on plastic bags are helping, they are not eradicating the problem, Papp said. 'Plastic pollution is a growing global problem,' she said. 'The overall percentage of plastic bags is still increasing … This increase is just slower in places with policies.' The evidence suggests some policies are more effective than others: Full bans made a bigger impact than partial bans, and fees seemed better than bans, said study coauthor Dr. Kimberly Oremus, an associate professor at the University of Delaware School of Marine Science and Policy. 'One hypothesis is that in at least some cases, the revenue from fees is being used to further reduce litter. In Washington, DC, for example, they use the revenue from plastic bag fees to clean up river shorelines,' Oremus said. However, the hypothesis has not been investigated, and there is not yet enough data to say for sure that fees are more effective than bans, she said. More must likely be done outside of these policies as well, Papp said. The United States needs regulations not just on the consumption of plastic bags but also on the production and supply of them, she added. There are also steps you can take so your plastic shopping bag doesn't end up in the environment, Papp said. For one, if you do use a plastic bag, don't let it fly away and create litter. Then, properly dispose of it — for example, you can take it to a plastic bag recycling station, she said. And you can always go back to the three R's, said Dr. Rebecca Taylor, an assistant professor of agricultural and consumer economics at the University of Illinois Urbana–Champaign. Reduce the number of plastic bags you use, reuse them when you can and recycle them when you must.
Medscape
28 minutes ago
- Medscape
Fast Five Quiz: CIDP Management
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a symptomatically treatable form of acquired neuropathy. The goals of treatment are decrease symptoms, delay progression, improve function of impacted areas, and achieve remission; if associated conditions are identified (HIV infection, lupus, paraproteinemia, and lymphoma), co-management of these diseases is indicated as well. How familiar are you with CIDP? Test your knowledge with this quick quiz. Medscape © 2025 WebMD, LLC Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape. Cite this: Jafar Kafaie, Christopher Luzzio, Florian P. Thomas. Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management - Medscape - Jun 19, 2025.
WebMD
37 minutes ago
- WebMD
FDA Approves First Twice-Yearly Shot to Prevent HIV
June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012, the drug – known as lenacapavir but sold under the name Yeztugo – offers a new way to protect against this life-threatening infection that affects more than a million people in the U.S. and has no cure. The shot is given before potential exposure to the virus. HIV spreads through unprotected sex and shared needles (including dirty needles from tattoos and body piercings). It weakens the immune system, and in its advanced stage, the body can no longer fight off infections, leading to acquired immune deficiency syndrome (AIDS). Only about a third of eligible people in the U.S. use available HIV prevention, with especially low use among women, Black/African American and Hispanic communities, and people in the South. This is mainly due to stigma, low awareness about existing options, and challenges with daily pills or frequent shots. Carlos del Rio, MD, a distinguished professor of medicine in the Division of Infectious Diseases at Emory University School of Medicine, said that getting a shot just twice a year could make it easier for people to stick with prevention. "Yeztugo could be the transformative PrEP [pre-exposure prophylaxis] option we've been waiting for – offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic," said del Rio, who is also co-director of the Emory Center for AIDS Research in Atlanta. Gilead, the drug's maker, said the FDA approved Yeztugo based on two major studies, which showed that it worked better than taking a daily pill form of PrEP in preventing HIV with a nearly 100% success rate. In one trial, none of the 2,134 women who received Yeztugo got HIV, while in the other, only two out of 2,179 people did. It was well tolerated with no new safety concerns, which led the academic journal Science to name lenacapavir as its 2024 "Breakthrough of the Year." Yeztugo attacks a protective shell that HIV needs to stay alive, which helps stop the virus from growing and spreading. Most HIV drugs only work at one part of the virus's life cycle, but Yeztugo works at several points. It also still works even if other HIV drugs have stopped working. It is given as a shot under the skin and is only for people who test negative for HIV. Before starting Yeztugo and before each shot, your provider will test for HIV to prevent the virus from developing resistance to the medication. The treatment begins with two shots and two tablets, followed by two more tablets the next day – then continues with one shot every six months. If a shot is delayed by over two weeks, a weekly pill can be used for up to six months. If over 28 weeks pass with no treatment, patients may need to restart. If a patient gets HIV while on Yeztugo, they'll need full HIV treatment, as Yeztugo alone isn't enough. Yeztugo helps lower the risk of HIV when taken as prescribed, along with safe sex practices like using condoms.
